Scope, Claims, and US Patent Landscape for US Drug Patent 9,724,358
What does US 9,724,358 claim in scope terms?
US Patent 9,724,358 is directed to a method of treating complicated skin and skin structure infections (cSSSI) in humans using intravenous 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline (including specified salts), with the key differentiator that GI adverse events associated with treatment are mild. The claims are structured as a classic “compound-in-use” and “use-quality” envelope: they do not claim new chemical entities as such, but they tightly define (i) indication, (ii) route and dosing, (iii) populations and infection characteristics, (iv) microbiology, and (v) tolerability endpoints.
Core claimed subject matter (Claim 1)
A method comprising:
- Indication: “complicated Skin and Skin Structure Infections” (cSSSI).
- Route: intravenous administration to a human subject.
- Active: 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof.
- Safety/Tolerability condition: GI adverse events are mild.
Claimed salt forms (Claims 2-3)
- Hydrochloride salt (Claim 2)
- Tosylate salt (Claim 3)
Claimed clinical setting / patient subsets (Claims 4-5)
- cSSSI where the subject is suffering from injury, major abscess, or cellulitis (Claim 4)
- Injury limited to traumatic injury (Claim 5)
Claimed dosing and administration frequency (Claims 6-7, 15)
- Daily IV dose range: about 50 mg to about 150 mg per day (Claim 6)
- Example daily dose: about 100 mg per day (Claim 7)
- Dosing frequency: once per day (Claim 15)
Claimed outcomes (Claims 8-9)
The claims bake in performance thresholds:
- Clinical success rate > about 93.2% (Claim 8)
- Microbiologically evaluable clinical success rate > about 93.7% (Claim 9)
Claimed microbiology targets (Claims 10-13)
cSSSI caused by:
- Staphylococcus aureus, Streptococci, or combination (Claim 10)
- S. aureus limited to MRSA or MSSA (Claim 11)
- Streptococci limited to beta Streptococci (Claim 12)
- Streptococcus specified as Streptococcus pyogenes (Claim 13)
Claimed infection morphology / signs (Claim 14)
cSSSI characterized by presence of one or more:
- erythema
- edema
- induration (Claim 14)
Claimed step-down / sequential regimen (Claims 16-19)
- Sequential IV followed by oral administration (Claim 16)
- Duration variants for the sequential regimen (Claim 17):
- IV+oral treatment up to and including about 14, 10, 9, 8, or 7 days
- IV to oral step-down windows (Claim 18):
- IV up to 7 days, followed by about 1 week or about 2 weeks oral
- Example schedule (Claim 19):
- IV about 4 days, total IV+oral about 10 days
Claimed tolerability endpoint phrased as non-discontinuation (Claim 20)
- GI adverse events “do not result in discontinuation of therapy” (Claim 20)
How is “mild GI adverse events” used to narrow infringement risk?
The patent’s legal center of gravity is the tolerability condition embedded in Claim 1, then supported by Claim 20. That approach matters because many cSSSI antibiotics have marketed or investigational profiles that achieve efficacy but differ in GI tolerability. Here, infringement scope depends on:
- The clinician performing or the label being consistent with “mild” GI AEs, and
- The method being tied to a regimen for which those AEs meet the claim’s condition (Claim 20 strengthens this by requiring no therapy discontinuation).
Claim architecture that limits overbroad reading
- Claim 1: broadest independent method claim but still tethered to the tolerability standard.
- Claims 2-3: narrow the salt form.
- Claims 4-5: narrow infection setting.
- Claims 6-7, 15: narrow dose range and schedule.
- Claims 8-9: narrow by success-rate thresholds.
- Claims 10-13: narrow by organism group and species, including MRSA/MSSA.
- Claims 14: narrow by clinical sign profile.
- Claims 16-19: narrow the dosing schedule variant to IV-then-oral with specific time boundaries.
- Claim 20: narrows tolerability via “no discontinuation.”
This is not simply a “minocycline class for skin infections” claim. The tolerability and quantitative success thresholds create a specific performance and monitoring envelope.
What is the practical “claims-to-therapy” map for design-around and marketing exposure?
Infringement-relevant parameters (highest leverage)
- Drug identity: 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline (or specified salts).
- Indication: complicated skin and skin structure infections.
- Route: intravenous.
- Tolerability: GI AEs are “mild,” and in dependent form do not lead to discontinuation.
- Dosing: about 50-150 mg/day; example 100 mg/day; once daily; and IV+oral step-down options with specified windows.
- Efficacy thresholds: clinical success rates above ~93.2% and microbiologically evaluable success above ~93.7%.
- Microbiology: S. aureus (MRSA/MSSA) and/or Streptococci including beta Streptococci / S. pyogenes.
Design-around levers (how competitors reduce risk)
- Change to a non-covered active: outside compound scope is the cleanest path.
- Avoid specified salt forms: if the product uses a different salt (not hydrochloride or tosylate) and the formulation is not the “salt thereof” encompassed by the claim construction, risk reduces. (Claim 1 covers “salt thereof,” but dependent claims specify examples.)
- Change dose range or dosing frequency: moving outside “about 50-150 mg/day” or “once per day” can reduce exposure to dependent claims 6-7 and 15.
- Avoid IV-first regimen: method claim 1 requires intravenous administration; sequential oral step-down is only claimed in dependent claims 16-19. A non-IV regimen could reduce literal coverage, but depends on claim construction and any doctrine-of-equivalents analysis.
- Remove the tolerability predicate from the claimed method: if the regimen is used in a setting where GI AEs are not “mild” or therapy discontinuations occur, the literal predicate may not be met for Claim 1/20.
- Target a different infection definition: avoid the “complicated cSSSI” definition or patient subset (injury, major abscess, cellulitis; traumatic injury).
- Avoid organism scope: if a competitor’s indicated pathogens exclude MRSA/MSSA and key Streptococci groups, it may avoid dependent claims 10-13.
What is the scope of organisms and infection presentations?
Claim 10-13 and Claim 14 create a fairly tight clinical picture:
Pathogen scope
- Staphylococcus aureus: MRSA and MSSA both included.
- Streptococci: beta Streptococci included.
- Specific species: Streptococcus pyogenes explicitly included.
Clinical presentation scope
- Presence of one or more of:
- erythema
- edema
- induration
Clinical syndromes and causative contexts
- cSSSI in the setting of:
- injury
- major abscess
- cellulitis
- injury limited to:
How do the numeric efficacy thresholds change the landscape?
Claims 8 and 9 require:
- Clinical success rate > about 93.2%
- Microbiologically evaluable clinical success rate > about 93.7%
This is unusual for method-of-treatment patents unless the specification ties those thresholds to trial results that can be mapped to clinical use. In infringement analysis, these metrics can create evidentiary hurdles for both:
- patent enforcement against a product that uses a different protocol or patient population, and
- challengers arguing lack of meeting performance requirements in practice.
For business and investment decisions, the consequence is straightforward: the strongest enforceability is when competitors target the same cSSSI setting, microbiology mix, and regimen that produced those success rates.
What is the step-down IV-to-oral regimen scope?
Claims 16-19 define sequential treatment. The claim language creates multiple “valid time-and-structure” regimens:
IV then oral (Claim 16)
- IV followed by oral administration.
Duration variants (Claim 17)
Total treatment period up to and including:
- 14 days
- 10 days
- 9 days
- 8 days
- 7 days
IV duration and oral window (Claim 18)
- IV for up to 7 days, then oral for about 1 week or about 2 weeks.
Example schedule (Claim 19)
- IV about 4 days
- Total IV+oral about 10 days
For a product development program, these time boundaries function like built-in protocol templates: replicating them increases exposure; deviating can reduce dependent claim coverage.
How does US 9,724,358 fit into the broader US “drug patent landscape”?
Based on the claim set alone, US 9,724,358 is best treated as:
- a method-of-use patent anchored to a specific antibiotic for a specific infection class, and
- a tolerability-and-efficacy framed enforcement layer over a compound that likely already had other chemistry or formulation protections elsewhere.
Landscape implications for freedom-to-operate (FTO)
For any IV therapy using the same active ingredient (or salts within claim 1’s scope), this patent creates a constraint on:
- product labeling wording,
- clinician workflow (route, dose, frequency),
- regimen duration,
- expected GI tolerability profile, and
- the trial-efficacy targets used to support approval claims.
Landscape implications for AB/therapeutic substitution and label design
Even if a competitor can avoid literal infringement by changing protocol or label, the patent’s tolerability predicate plus numeric success-rate requirements often makes label-only “carve-outs” less protective than normal, because enforcement can focus on actual administered methods.
Landscape implications for generic entry
If an ANDA is for the same active ingredient and seeks the same indication and regimen, the method-use claims can become a bottleneck. If instead a generic uses a different regimen not meeting dependent claim features (IV timing, dose range, once daily frequency, and sequential schedule), exposure can shift to whether Claim 1’s core requirements are still met.
Claim-by-claim scope summary table
| Claim |
What it adds / limits |
Key scope effect |
| 1 |
IV use of 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline for cSSSI; GI AEs are mild |
Core independent coverage; tolerability predicate is central |
| 2 |
Hydrochloride salt |
Narrows to specific salt |
| 3 |
Tosylate salt |
Narrows to specific salt |
| 4 |
cSSSI with injury, major abscess, or cellulitis |
Narrows patient/infection context |
| 5 |
Injury is traumatic injury |
Further narrows Claim 4 |
| 6 |
Dose about 50-150 mg/day IV |
Narrows dosing range |
| 7 |
About 100 mg/day IV |
Narrows to a specific exemplar |
| 8 |
Clinical success rate > ~93.2% |
Adds efficacy performance threshold |
| 9 |
Microbiologically evaluable success rate > ~93.7% |
Adds stricter efficacy metric |
| 10 |
Pathogens: S. aureus or Streptococci (or combo) |
Narrows pathogen scope |
| 11 |
S. aureus is MRSA or MSSA |
Narrows to resistance status |
| 12 |
Streptococci are beta Streptococci |
Narrows Streptococcus group |
| 13 |
Streptococcus pyogenes |
Adds specific species |
| 14 |
cSSSI characterized by erythema, edema, induration |
Narrows clinical presentation |
| 15 |
Once per day dosing |
Narrows administration schedule |
| 16 |
IV followed by oral |
Adds step-down structure |
| 17 |
Total treatment up to 14/10/9/8/7 days |
Narrows duration variants |
| 18 |
IV up to 7 days, then oral ~1-2 weeks |
Narrows step-down timing |
| 19 |
Example: IV ~4 days, total ~10 days |
Provides a concrete protocol |
| 20 |
GI AEs do not cause therapy discontinuation |
Strengthens tolerability predicate |
Key Takeaways
- US 9,724,358 claims a specific method: IV treatment of complicated skin and skin structure infections with 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline (or salts), where GI adverse events are mild.
- Coverage is tightened through dependent claim feature bundles: salt identity (HCl, tosylate), patient/infection context (injury/major abscess/cellulitis; traumatic injury), dosing (about 50-150 mg/day; once daily; exemplar 100 mg/day), pathogens (MRSA/MSSA and beta Streptococci including S. pyogenes), clinical signs (erythema/edema/induration), and sequential IV-to-oral duration templates.
- The inclusion of numeric success-rate thresholds (clinical success > ~93.2%; microbiologically evaluable > ~93.7%) and the non-discontinuation GI predicate (Claim 20) increases the need for competitors to match not just the compound and indication, but also the protocol and outcomes profile tied to the claimed method.
FAQs
1. Is US 9,724,358 a composition patent or a method-of-use patent?
It is a method-of-treatment patent framed around IV administration for cSSSI with a tolerability requirement.
2. What is the claimed active ingredient?
9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline, including “a salt thereof.”
3. What infection type is covered?
Complicated skin and skin structure infections (cSSSI), with dependent claims narrowing to injury, major abscess, cellulitis, and clinical signs (erythema, edema, induration).
4. What is the tolerability limitation that differentiates the patent?
The method requires GI adverse events are mild, and dependent Claim 20 requires GI AEs do not result in discontinuation of therapy.
5. What regimen parameters increase infringement risk?
Using the drug intravenously once daily in the claimed dose range (about 50-150 mg/day, exemplar 100 mg/day) and, where applicable, matching the IV-to-oral step-down timing templates (IV up to 7 days, then oral about 1-2 weeks; example IV about 4 days with total about 10 days).
References
[1] US Patent 9,724,358 (claims provided in prompt).
